Nesfatin-1 as a potential marker for functional hypothalamic amenorrhea

References

• Oh-I S, Shimizu H, Satoh T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006;443(7112):709–712.
   PubMed Web of Science ®Google Scholar
• Hatef A, Unniappan S. Gonadotropin-releasing hormone, kisspeptin, and gonadal steroids directly modulate nucleobindin-2/nesfatin-1 in murine hypothalamic gonadotropin-releasing hormone neurons and gonadotropes. Biol Reprod. 2017;96(3):635–651.
   PubMed Web of Science ®Google Scholar
• Pan W, Hsuchou H, Kastin AJ. Nesfatin-1 crosses the blood–brain barrier without saturation. Peptides. 2007;28(11):2223–2228.
   PubMed Web of Science ®Google Scholar
• Price TO, Samson WK, Niehoff ML, et al. Permeability of the blood–brain barrier to a novel satiety molecule nesfatin-1. Peptides. 2007;28(12):2372–2381.
   PubMed Web of Science ®Google Scholar
• Stengel A, Goebel M, Yakubov I, et al. Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology. 2009;150(1):232–238.
   PubMed Web of Science ®Google Scholar
• Atsuchi K, Asakawa A, Ushikai M, et al. Centrally administered nesfatin-1 inhibits feeding behaviour and gastroduodenal motility in mice. Neuroreport. 2010;21(15):1008–1011.
   PubMed Web of Science ®Google Scholar
• Merali Z, Cayer C, Kent P, et al. Nesfatin-1 increases anxiety- and fear-related behaviors in the rat. Psychopharmacology (Berl). 2008;201(1):115–123.
   PubMed Web of Science ®Google Scholar
• Yosten GLC, Samson WK. The anorexigenic and hypertensive effects of nesfatin-1 are reversed by pretreatment with an oxytocin receptor antagonist. Am J Physiol Regul Integr Comp Physiol. 2010;298(6):R1642–7.
   PubMed Web of Science ®Google Scholar
• Ramanjaneya M, Chen J, Brown JE, et al. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology. 2010;151(7):3169–3180.
   PubMed Web of Science ®Google Scholar
• Xu Y-Y, Ge J-F, Qin G, et al. Acute, but not chronic, stress increased the plasma concentration and hypothalamic mRNA expression of NUCB2/nesfatin-1 in rats. Neuropeptides. 2015;54:47–53.
   PubMed Web of Science ®Google Scholar
• Navarro VM, Kaiser UB. Metabolic influences on neuroendocrine regulation of reproduction. Curr Opin Endocrinol Diabetes Obes. 2013;20(4):335–341.
   PubMedGoogle Scholar
• García-Galiano D, Tena-Sempere M. Emerging roles of NUCB2/nesfatin-1 in the metabolic control of reproduction. Curr Pharm Des. 2013;19(39):6966–6972.
   PubMed Web of Science ®Google Scholar
• Garcia-Galiano D, Navarro VM, Roa J, et al. The anorexigenic neuropeptide, nesfatin-1, is indispensable for normal puberty onset in the female rat. J Neurosci. 2010;30(23):7783–7792.
   PubMed Web of Science ®Google Scholar
• Dore R, Levata L, Lehnert H, et al. Nesfatin-1: functions and physiology of a novel regulatory peptide. J Endocrinol. 2017;232(1):R45–R65.
   PubMed Web of Science ®Google Scholar
• Treen AK, Luo V, Belsham DD. Phoenixin activates immortalized GnRH and kisspeptin neurons through the novel receptor GPR173. Mol Endocrinol. 2016;30(8):872–888.
   PubMedGoogle Scholar
• Pałasz A, Rojczyk E, Bogus K, et al. The novel neuropeptide phoenixin is highly co-expressed with nesfatin-1 in the rat hypothalamus, an immunohistochemical study. Neurosci Lett. 2015;592:17–21.
   PubMed Web of Science ®Google Scholar
• Gordon CM, Ackerman KE, Berga SL, et al. Functional hypothalamic amenorrhea: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(5):1413–1439.
   PubMed Web of Science ®Google Scholar
• Ogiso K, Asakawa A, Amitani H, et al. Plasma nesfatin-1 concentrations in restricting-type anorexia nervosa. Peptides. 2011;32(1):150–153.
   PubMed Web of Science ®Google Scholar
• Saldanha JF, Carrero JJ, Lobo JC, et al. The newly identified anorexigenic adipokine nesfatin-1 in hemodialysis patients: Are there associations with food intake, body composition and inflammation? Regul Pept. 2012;173(1-3):82–85.
   PubMedGoogle Scholar
• Aydin S, Dag E, Ozkan Y, et al. Nesfatin-1 and ghrelin levels in serum and saliva of epileptic patients: Hormonal changes can have a major effect on seizure disorders. Mol Cell Biochem. 2009;328(1–2):49–56.
   PubMed Web of Science ®Google Scholar
• Hofmann T, Elbelt U, Ahnis A, et al. Sex-specific regulation of NUCB2/nesfatin-1: Differential implication in anxiety in obese men and women. Psychoneuroendocrinology. 2015;60:130–137.
   PubMed Web of Science ®Google Scholar
• Altıncık A, Sayın O. Serum nesfatin-1 levels in girls with idiopathic central precocious puberty. J Clin Res Pediatr Endocrinol. 2018;10(1):8–12.
   PubMed Web of Science ®Google Scholar
• Li Q-C, Wang H-Y, Chen X, et al. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept. 2010;159(1–3):72–77.
   PubMedGoogle Scholar
• Hofmann T, Ahnis A, Elbelt U, et al. NUCB2/nesfatin-1 is associated with elevated levels of anxiety in anorexia nervosa. PLoS One. 2015;10(7):e0132058.
   PubMed Web of Science ®Google Scholar
• Çatlı G, Anık A, Küme T, et al. Serum nesfatin-1 and leptin levels in non-obese girls with premature thelarche. J Endocrinol Invest. 2015;38(8):909–913.
   PubMed Web of Science ®Google Scholar
• Catak Z, Yavuzkir S, Kocdemir E, et al. NUCB2/nesfatin-1 in the blood and follicular fluid in patients with polycystic ovary syndrome and poor ovarian response. J Reprod Infertil. 2019;20(4):225–230.
   PubMedGoogle Scholar
• Abaci A, Catli G, Anik A, et al. The relation of serum nesfatin-1 level with metabolic and clinical parameters in obese and healthy children. Pediatr Diabetes. 2013;14(3):189–195.
   PubMed Web of Science ®Google Scholar
• Tsuchiya T, Shimizu H, Yamada M, et al. Fasting concentrations of nesfatin-1 are negatively correlated with body mass index in non-obese males. Clin Endocrinol (Oxf). 2010;73(4):no–no.
   Web of Science ®Google Scholar
• Anwar GM, Yamamah G, Ibrahim A, et al. Nesfatin-1 in childhood and adolescent obesity and its association with food intake, body composition and insulin resistance. Regul Pept. 2014;188:21–24.
   PubMedGoogle Scholar
• Tan BK, Hallschmid M, Kern W, et al. Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/NUCB-2, in obese humans: evidence of nesfatin-1/NUCB-2 resistance and implications for obesity treatment. J Clin Endocrinol Metab. 2011;96(4):E669–E673.
   PubMed Web of Science ®Google Scholar